Hospital Universitario Hm Sanchinarro

At Hospital Universitario Hm Sanchinarro, the strongest research focus is on neoplasms and advanced cancer care, with many studies exploring new options for breast cancer, non-small cell lung cancer, colorectal cancer, ovarian cancer, and other hard-to-treat solid tumors. The work is centered on testing new therapies and combinations to improve response, extend survival, and address disease that has returned or no longer responds well to standard treatment.

• Advanced and metastatic solid tumors, including tumor-agnostic studies for biomarker-defined cancers
• Breast cancer, especially hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative disease
• Lung, colorectal, gastric, pancreatic, urothelial, and head and neck cancers
• Purpose: evaluating novel anti-cancer treatments, combination strategies, and precision-medicine approaches

The CIOCC Phase I trials unit is especially active in early clinical research, helping identify promising treatment options for patients with advanced malignancies.

A major portion of the site’s portfolio addresses breast neoplasms and gynecological cancers, including ovarian cancer, endometrial cancer, cervical cancer, and related conditions. These studies often aim to improve treatment effectiveness in hormone-driven disease, resistant disease, and cancers with specific molecular features.

• Hormone receptor-positive and HER2-negative breast cancer
• HER2-positive, HER2-low, and triple-negative breast cancer
• Ovarian, endometrial, cervical, fallopian tube, and primary peritoneal cancers
• Purpose: improving outcomes through targeted therapy, endocrine-based strategies, and better treatment selection

Research at this Madrid site also includes studies designed to refine care before and after surgery, especially for patients with early-stage or high-risk disease.

The site supports extensive research in respiratory tract diseases and digestive system diseases, with many trials focused on lung cancer, gastric cancer, esophageal cancer, pancreatic cancer, and colorectal cancer. This reflects a broad effort to test new treatment approaches for some of the most common and challenging cancers.

• Non-small cell lung cancer and small cell lung cancer
• Gastric, esophageal, gastroesophageal junction, and pancreatic cancers
• Colorectal cancer and rectal cancer, including biomarker-selected disease
• Purpose: assessing treatment effectiveness and exploring precision oncology options

Many of these studies are designed for patients with advanced or recurrent disease, where new therapies may offer additional benefit beyond standard care.

Clinical research also covers hemic and lymphatic diseases and immune system diseases, including multiple myeloma, acute myeloid leukemia, lymphoma, and myelodysplastic syndromes. These trials are aimed at improving disease control, deepening responses, and supporting patients whose blood cancers have relapsed or are difficult to treat.

• Multiple myeloma and newly diagnosed or relapsed disease
• Acute myeloid leukemia, myelodysplastic syndrome, and related blood disorders
• B-cell, diffuse large B-cell, follicular, and other non-Hodgkin lymphomas
• Purpose: testing new immunotherapy, targeted therapy, and treatment-combination approaches

The research program at Hospital Universitario Hm Sanchinarro includes both first-in-human studies and later-stage trials in hematologic malignancies.

A distinctive feature of the site’s clinical research is its strong emphasis on precision oncology, with studies guided by tumor markers, gene alterations, and other biological features. Trials in this area include cancers with KRAS, RET, MET, EGFR, BRCA, and other actionable changes, reflecting a move toward more personalized treatment choices.

• Biomarker-selected solid tumors across multiple cancer types
• Targeted studies in mutation-defined lung, breast, ovarian, and colorectal cancers
• Research involving molecularly categorized bladder cancer and other genomically defined tumors
• Purpose: matching patients to therapies based on tumor biology and improving treatment precision

This focus supports the development of more tailored cancer care and helps identify which patients are most likely to benefit from specific treatments.

Beyond oncology, the site includes trials in selected nervous system diseases, cardiovascular diseases, immune-related conditions, and other areas such as migraine, asthma, chronic obstructive pulmonary disease, and Alzheimer’s disease. These studies broaden the research portfolio and address symptoms, complications, and comorbidities that can affect patients’ overall health.

• Migraine and chronic headache disorders
• Asthma, COPD, and other respiratory conditions
• Supportive care topics such as chemotherapy-related side effects and thrombocytopenia
• Purpose: improving symptom control, treatment tolerance, and quality of life

The breadth of research at this hospital and clinic setting shows a commitment to both cancer innovation and selected non-oncology studies that may improve patient care more broadly.